NMDA Antagonists for Viral Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral infections, particularly those affecting the central nervous system like COVID-19, face challenges in effectively preventing or reducing neurological side effects and damage, as existing medications often have off-target effects and limited efficacy in addressing neuroinflammation and neuronal damage.
Innovation Solution
Administration of N-methyl-D-aspartic acid receptor (NMDA) antagonists, such as memantine and ifenprodil, to prevent or treat viral-induced neuropathologies by targeting the NMDA receptors, reducing excitotoxicity, and modulating astrocyte and microglial responses, potentially combined with anti-viral therapies and steroids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used to treat viral infections, then the virus infection can be targeted, but off-target effects and limited efficacy in addressing neuroinflammation occur
Solution Approach 1:
The treatment approach is segmented into two distinct components: (1) anti-viral therapy to target the SARS-CoV-2 infection, and (2) NMDA receptor antagonism to specifically address neuroinflammation and excitotoxicity. This segmentation allows each treatment to target its specific mechanism without the off-target effects of broad-spectrum medications.
Solution Approach 2:
NMDA receptor antagonists serve as an intermediary mechanism that addresses the downstream pathological effects (excitotoxicity and neuroinflammation) caused by viral infection. Rather than directly targeting the virus, this intermediary approach targets the cellular mechanisms disrupted by the infection, thereby protecting neurons while the anti-viral therapy eliminates the pathogen.
2Object-affected harmful factors
If NMDA receptor antagonists are used to prevent neuroinflammation, then neuronal damage is reduced, but the mechanism of action requires precise targeting of NMDA receptors
Solution Approach 1:
The patent utilizes parameter changes in the form of selective NMDA receptor antagonist medications with specific binding affinities. By selecting agents that preferentially bind to NMDA receptors over other neuronal receptors, the treatment achieves precise targeting. This pharmacological parameter selection allows effective reduction of excitotoxicity without requiring complex delivery systems or mechanisms.
3Reliability
If early prophylactic treatment is administered, then neurological symptoms are prevented, but treatment must be initiated before symptom onset
Solution Approach 1:
The patent implements preliminary action by administering NMDA receptor antagonists prophylactically before neurological symptoms manifest. This preliminary treatment establishes protective mechanisms against excitotoxicity and neuroinflammation before they can cause damage. The treatment window is opened early in the disease course, allowing prevention of neuronal injury before it occurs.
Solution Approach 2:
The NMDA receptor antagonist performs preliminary anti-action by blocking the excitotoxic pathway before viral-induced glutamate release can cause neuronal damage. This preemptive blockade of the NMDA receptor prevents the cascade of events leading to neuroinflammation and cell death, countering the harmful effects before they manifest clinically.
Data Source
AI summary
This disclosure relates to methods for the prevention and/or treatment of neurological adverse effects caused by viral infections in a subject. In some aspects, the methods include administration of at least one N-methyl-D-aspartic acid receptor (NMDAR) antagonist to a subject as a preventative treatment. In other aspects, the NMDAR antagonists may be used as a treatment following a viral infection or suspected viral infection.